home All News open_in_new Full Article

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up […]


today 32 h. ago attach_file Other

attach_file Technology
attach_file Economics
attach_file Other
attach_file Events
attach_file Transport
attach_file Economics
attach_file Other
attach_file Economics
attach_file Events
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Politics
attach_file Economics
attach_file Society
attach_file Politics
attach_file Economics
attach_file Events
attach_file Other


ID: 48666576
Add Watch Country

arrow_drop_down